Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer

MLA

Martin G. Pomper, et al. “Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.” Journal of Urology, vol. 204, Sept. 2020, pp. 496–502. EBSCOhost, https://doi.org/10.1097/ju.0000000000001064.

APA

Martin G. Pomper, Mario A. Eisenberger, Ramy Sedhom, Kenneth J. Pienta, Michael A. Gorin, Mark C. Markowski, Wei Fu, Steven P. Rowe, & Javaughn Corey R. Gray. (2020). Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer. Journal of Urology, 204, 496–502. https://doi.org/10.1097/ju.0000000000001064

Chicago

Martin G. Pomper, Mario A. Eisenberger, Ramy Sedhom, Kenneth J. Pienta, Michael A. Gorin, Mark C. Markowski, Wei Fu, Steven P. Rowe, and Javaughn Corey R. Gray. 2020. “Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.” Journal of Urology 204 (September): 496–502. doi:10.1097/ju.0000000000001064.